Blood-brain barrier degradation (BBB degradation)

Blood-brain barrier (BBB) degradation refers to the structural and functional breakdown of the highly selective semipermeable border that separates the circulating blood from the brain and extracellular fluid in the central nervous system. This process is characterized by the disruption of tight junctions between endothelial cells, enzymatic digestion of the basement membrane by matrix metalloproteinases (MMPs), and dysfunction of the neurovascular unit, including astrocytes and pericytes (Zlokovic, 2011, Nature). While BBB degradation is a hallmark of many pathological states such as ischemic stroke, Alzheimer’s disease, and multiple sclerosis, it is also occasionally induced therapeutically to facilitate the delivery of large-molecule drugs or chemotherapy to the brain (Abbott et al., 2010, Neurobiology of Disease). From a pharmacological perspective, 'BBB degradation' is not a single molecular target but a complex physiological event. Therapeutic strategies generally focus on either preventing pathological degradation using MMP inhibitors and anti-inflammatory agents or inducing transient, reversible degradation via hypertonic mannitol or focused ultrasound to bypass the barrier (Daneman & Prat, 2015, Cold Spring Harbor Perspectives in Biology). Monitoring of this process is typically achieved through imaging techniques like DCE-MRI or biochemical analysis of the CSF/serum albumin index, which serves as a gold standard for barrier integrity.

Other names

Blood-brain barrier disruptionBBB breakdownBlood-brain barrier hyperpermeabilityNeurovascular unit dysfunctionIncreased BBB permeability

Degradation is primarily mediated by the upregulation of matrix metalloproteinases (MMPs), particularly MMP-9 and MMP-2, which enzymatically cleave tight junction proteins like Claudin-5, Occludin, and ZO-1, or via osmotic shrinking of endothelial cells using hypertonic solutions to physically pull junctions apart.